How should I manage a patient with a history of Graves disease who discontinued methimazole months ago and now presents with suppressed TSH, palpitations, headaches, blurry vision, and photophobia?

Immediate Management: Restart Methimazole and Initiate Beta-Blockade

This patient has relapsed Graves' disease with symptomatic thyrotoxicosis requiring immediate reinitiation of antithyroid drug therapy. The suppressed TSH (0.012) combined with palpitations, headaches, blurry vision, and photophobia indicates active hyperthyroidism with concerning ocular symptoms that may represent Graves' ophthalmopathy (GO).

Initial Diagnostic Workup

Before restarting therapy, obtain:

• Free T4 and total T3 to confirm thyrotoxicosis severity 1
• Complete blood count with differential and liver function tests (baseline before methimazole) 1
• TSH receptor antibodies (TRAb) to assess disease activity and predict remission likelihood 1
• Ophthalmologic evaluation urgently given photophobia and blurry vision to assess for active GO 2

The photophobia and blurry vision are red flags that cannot be ignored—these may indicate Graves' ophthalmopathy, which fundamentally changes management decisions.

Immediate Pharmacologic Management

1. Restart Methimazole

Methimazole should be used in virtually every patient who chooses antithyroid drug therapy for Graves' disease 1, 3. Start with:

• 15-20 mg daily for symptomatic patients with likely elevated free T4 1, 4
• Single daily dosing is sufficient given methimazole's pharmacokinetics 4

2. Beta-Adrenergic Blockade

Beta-blockers should be given to patients with symptomatic thyrotoxicosis and resting heart rates exceeding 90 bpm or cardiovascular symptoms 1. Options include:

• Atenolol or propranolol for immediate symptom control (palpitations, tremor) 5
• Continue until euthyroid status achieved

Critical Safety Counseling

Before restarting methimazole, the patient must be warned to immediately stop the medication and contact you if they develop 1:

• Fever or sore throat (agranulocytosis warning signs)
• Jaundice, light-colored stools, or dark urine (hepatotoxicity)
• Severe rash, joint pain, or abdominal pain

This is non-negotiable given methimazole's potentially life-threatening adverse effects 3.

Definitive Treatment Decision

Since this patient has relapsed after completing a course of methimazole, consideration should be given to definitive treatment with radioactive iodine or thyroidectomy 1. However, the presence of photophobia and blurry vision complicates this decision:

If Active/Moderate-to-Severe GO is Confirmed:

• Radioactive iodine is contraindicated 6
• Continue methimazole or proceed to thyroidectomy 1, 2
• Thyroidectomy requires preoperative euthyroid status with methimazole plus potassium iodide in the immediate preoperative period 1

If NO Active GO or Only Mild GO:

Three equally acceptable options 1:

1. Radioactive iodine therapy (10-15 mCi single dose to render hypothyroid) 1
   • If mild GO present, give concurrent corticosteroids 1
   • Pretreat with methimazole if free T4 is 2-3× upper limit of normal 1
2. Long-term low-dose methimazole (alternative to definitive therapy) 1
   • Studies show 78-85% remain euthyroid on long-term therapy 7, 8
   • Mean dose decreases to 2.8-5 mg daily over time 8
   • Provides 95.8% time in euthyroid state vs. 90.4% with short-term therapy 7
3. Total thyroidectomy by high-volume surgeon 1

Monitoring Protocol

First 2 Months:

• Free T4 and total T3 every 4-6 weeks 1
• Monitor for transition to hypothyroidism (common with thyroiditis component)

Ongoing:

• Once euthyroid, continue methimazole for 12-18 months minimum before considering discontinuation 1
• Measure TRAb before stopping therapy—normal levels indicate greater remission chance 1
• If TRAb remains elevated at 12-18 months, either continue long-term methimazole or proceed to definitive therapy 1

Common Pitfalls to Avoid

1. Do not ignore the ocular symptoms—failure to evaluate for GO can lead to vision-threatening complications and inappropriate RAI therapy 2
2. Do not use propylthiouracil unless first trimester pregnancy—methimazole has superior safety profile 1, 4, 3
3. Do not delay beta-blockade in symptomatic patients—cardiovascular complications from prolonged tachycardia increase morbidity 1
4. Do not restart methimazole without baseline CBC and LFTs—you need comparison values if toxicity develops 1
5. Do not assume this is simple relapse—the photophobia/blurry vision pattern demands ophthalmologic assessment before committing to RAI 2

Bottom Line Algorithm

Immediate (Today):

• Obtain free T4, T3, CBC, LFTs, TRAb
• Urgent ophthalmology referral for GO assessment
• Start methimazole 15-20 mg daily + beta-blocker
• Provide written agranulocytosis/hepatotoxicity warnings

Within 1-2 Weeks:

• Review labs and ophthalmology findings
• If active/moderate-to-severe GO: continue methimazole, avoid RAI
• If no/mild GO: discuss definitive therapy options (RAI vs. surgery vs. long-term methimazole)

Long-term:

• Given relapse after prior course, definitive therapy (RAI or surgery) is preferred over another 12-18 month course 1
• Exception: patient preference for long-term low-dose methimazole is reasonable alternative with excellent outcomes 7, 8, 9